


Dx&Vx

IR Letter

(Apr. 2025)



Dx&Vx Business Roadmap



Medical Diagnostics

Dx&Vx's genomic diagnostics and in vitro diagnostics contribute to reducing healthcare costs and improving treatment outcomes. Genomic diagnostic technologies enable more precise and personalized treatments, combined with new drug developments, driving innovation in the medical field. Our companion diagnostic services enhance the efficacy of both our own and third-party drug developments, minimizing side effects and facilitating the development of personalized treatment options for patients.

Genomic Diagnostics
In Vitro Diagnostics and CDMO
Genomics CRO
Companion Diagnostic Services (CtiDex)



Consumer Healthcare

Using our diagnostic technologies, we provide integrated consumer healthcare solutions based on the microbiome for disease prevention, treatment, and management. Our services include health functional foods for prevention, general pharmaceuticals and prescription drugs for treatment, and products for lifestyle and hygiene management. We target the global market and continue to achieve high sales growth.

Microbiome-based Therapeutic Adjuncts
Nutrition Products
Domestic and International CSO
Functional Skincare/Personal Hygiene Products



Drug Development

We are actively advancing the development of various novel therapeutics, including the long-term storage mRNA vaccine platform, immuno-oncology therapies, oral obesity treatments, and vaccines and therapeutics for infectious diseases, while expanding collaborations with global pharmaceutical companies. In 2025, we expect major platform technologies to yield tangible results, driving the commercialization of new drug development, revenue growth, and the establishment of a sustainable clinical reinvestment cycle to ensure long-term growth.

Vaccine
mRNA Vaccine and Diagnostic Platform
Obesity and Metabolic Diseases
Anticancer Drug
Ophthalmic Therapeutics
Antiviral Drug



Digital Healthcare

Dx&Vx is on the verge of launching K-hub, a bio-pharmaceutical portal, combined with our genomic analysis platform and telemedicine services. We aim to shift from a treatment-centric to a prevention and management-focused approach in healthcare services, ultimately aiming to develop a Clinical Decision Support System (CDSS) to assist medical professionals in their decision-making.

K-hub
Telemedicine Services
AI-based Drug Development Platform
Smart Diagnostic Devices

Performance Summary for March 2025



Initiated full-scale negotiations for global out-licensing of mRNA cancer vaccine



Filed an additional patent for a novel GLP-1RA oral anti-obesity compound



Participated in Bio-Europe Spring, Europe's largest pharmaceutical and biotech partnering conference



Drug Development

Initiated full-scale negotiations for global out-licensing of mRNA cancer vaccine ▼

DXVX has initiated full-scale negotiations for the global out-licensing of its proprietary mRNA-based cancer vaccine. Recent preclinical efficacy studies have demonstrated strong anti-tumor activity, showing results comparable to or exceeding those of clinical-stage technologies currently in the market, thereby providing solid justification for licensing discussions. A patent application for the candidate was filed in 2023.

The company is currently engaged in detailed discussions with global pharmaceutical partners, including term sheet negotiations, as licensing procedures move forward. Leveraging its safety and efficacy data, DXVX aims to achieve tangible licensing outcomes within a short timeframe.

Filed an additional patent for a novel GLP-1RA oral anti-obesity compound ▼

DXVX has filed an additional patent for a novel compound structure related to its oral anti-obesity treatment based on GLP-1 receptor agonists (GLP-1RA). This is the third patent filing following two applications submitted last year, and it forms part of the company's strategy to secure technological leadership and enhance global competitiveness. Since the early stages of R&D, DXVX has implemented an intellectual property (IP)-centered protection strategy for this pipeline. The latest patent filing represents a meaningful step forward in expanding global licensing and partnership opportunities, defending against competitive patents, and reinforcing the foundation for future commercialization.

Our company has recently conducted preclinical efficacy studies to validate the compound's therapeutic potential, securing key data required for clinical entry, and plans to conduct additional studies to further evaluate its safety and efficacy.

Participated in Bio-Europe Spring, Europe's largest pharmaceutical and biotech partnering conference ▼

DXVX has filed an additional patent for a novel compound structure related to its oral anti-obesity drug candidate based on GLP-1 receptor agonists (GLP-1RA). This marks the third filing following two patent applications submitted last year and is part of the company's broader strategy to secure technological leadership and strengthen its global competitiveness.

From the early stages of R&D, DXVX has pursued an IP-centered strategy to protect its innovations, and this latest filing represents a meaningful step toward expanding global licensing opportunities, defending against competitive patents, and reinforcing the foundation for commercialization. Our company has also conducted preclinical efficacy studies to evaluate the candidate's therapeutic potential, securing key data required for clinical entry, and plans to carry out additional studies to further validate its safety and efficacy.

Compliance Notice

This document is prepared solely for informational purposes to assist investors' understanding. It is based on data and information considered reliable, and has been diligently compiled; however, we do not guarantee its accuracy or completeness. Investment decisions should be made based on the investor's own judgment and responsibility. Under no circumstances can this material be used as legal evidence of liability for investment results.